Predictive AI, Longevity and Biological Foresight

Benjamin Ballout’s 2026 research explores how artificial intelligence may contribute to earlier, more personalized approaches to health risk assessment and biological aging.

Benjamin Ballout, Chairman & CEO of Diplomatic Trade Ltd and founder of Z-Ai Predictive Lab™, has expanded his research into predictive artificial intelligence, longevity science and medical imaging.

From Reactive Medicine to Predictive Systems

In Before Disease AI, Predictive Longevity, and the Coming Age of Biological Foresight, posted on SSRN in September 2026, Ballout examines the emerging use of artificial intelligence, biological-age measurements, multi-omics and digital models as tools that may help identify patterns associated with health risk before conventional clinical symptoms appear.

Predictive Radiology

A second 2026 paper, Biological Foresight II / Predictive Radiology, considers the potential role of imaging biomarkers, MRI, CT, radiomics and organ-specific biological aging in predictive medicine. The paper explores how medical imaging data could become part of broader AI-supported frameworks for preventive and precision healthcare.

A Broader Research Agenda

Ballout’s research portfolio also addresses predictive AI, global governance, financial systems and international policy. The common theme is the use of forecasting and data-driven systems to support earlier and more informed decision-making across complex domains.

These publications present research concepts and analysis. They should not be interpreted as evidence that a clinical product has been validated, approved, or deployed.

Read the Research

Ballout’s research papers are available through his SSRN author profile.

Learn more about Benjamin Ballout and Diplomatic Trade leadership.